Skip to main content

Table 3 Summary of treatment-emergent adverse events

From: A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis

 

All Causality TEAEs

Treatment-Related AE

ETN–ETN (n = 21)

ETN–ACT (n = 20)

ACT (n = 18)

Total (N = 59)

ETN–ETN (n = 21)

ETN–ACT (n = 20)

ACT (n = 18)

Total (N = 59)

Patients with TEAEs, n (%)

14 (66.7 %)

14 (70.0 %)

10 (55.6 %)

38 (64.4 %)

9 (42.9 %)

10 (50.0 %)

8 (44.4 %)

27 (45.8 %)

Total number of TEAEs

22

38

25

85

11

22

13

46

Patients with SAEs, n (%)

0 (0.0 %)

0 (0.0 %)

1 (5.6 %)

1 (1.7 %)

0 (0.0 %)

0 (0.0 %)

0 (0.0 %)

0 (0.0 %)

Total number of SAEs

0

0

1

1

0

0

0

0

Permanent discontinuation due to AE, n (%)

1 (4.8 %)

0

1 (5.6 %)

2 (3.4 %)

  1. Abbreviations: ACT acitretin, AE adverse event, ETN etanercept, SAE serious adverse event, TEAE treatment-emergent adverse event